medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number S2

Ann Hepatol 2013; 12 (S2)

An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver

Chávez-Tapia NC, Ridruejo E, Alves MA, Bessone F, Daruich J, Sánchez-Ávila JF, Cheinquer H, Zapata R, Uribe M, Bosques-Padilla F, Gadano A, Soza A, Dávalos-Moscol M, Marroni C, Muńoz-Espinoza L, Castro-Narro G, Paraná R, Méndez-Sánchez N

Language: English
References: 145
Page: 3-35
PDF size: 341.68 Kb.


ABSTRACT

Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.


REFERENCES

  1. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493-8.

  2. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9; e118.

  3. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827, 827; e821.

  4. Gonzalez SA, Keeffe EB. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (NY) 2011; 7: 366- 73.

  5. Muir AJ. IL28B in the Era of Direct-acting Antivirals for Hepatitis C. J Clin Gastroenterol 2013; 47: 222-7. Doi: 10.1097/MCG.0b013e3182680221.

  6. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.

  7. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.

  8. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

  9. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.

  10. Victrelis (boceprevir) capsules [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 2011.

  11. Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; May 2011.

  12. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S57-S64.

  13. Uribe M, Gutierrez-Grobe Y, Kobashi-Margain RA, Mendez- Sanchez N. Noninvasive markers of liver fibrosis in Latin America and Mexico. Ann Hepatol 2010; 9(Suppl.): 43-8.

  14. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-5.

  15. Castera L, Bedossa P. How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy? Liver Int 2011; 31(Suppl. 1): 13-7.

  16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.

  17. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-1302; e1294.

  18. Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, et al. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther 2012; 35: 92-104.

  19. Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-13.

  20. Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 1995; 269: 1854-7.

  21. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008; 47: 332-42.

  22. Degos F, Perez P, Roche B, Mahmoudi A, Asselineau J, Voitot H, Bedossa P. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-21.

  23. Forns X, Ampurdančs S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.

  24. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

  25. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, Pawlotsky JM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935-42.

  26. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99: 271-9.

  27. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, Lin R, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39: 1239-47.

  28. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.

  29. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42: 282-92.

  30. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005; 40: 867-72.

  31. Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 2006; 44: 925-35.

  32. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007; 45: 297-306.

  33. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.

  34. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008; 47: 789-98.

  35. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.

  36. Arena U, Vizzutti F, Abraldes JG, Corti G, Stasi C, Moscarella S, Milani S, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57: 1288-93.

  37. Lupsor M, Badea R, Stefanescu H, Grigorescu M, Sparchez Z, Serban A, Branda H, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. J Gastrointestin Liver Dis 2008; 17: 155-63.

  38. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56: 55-62.

  39. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

  40. Strader DB, Seeff LB. A brief history of the treatment of viral hepatitis C. Clinical Liver Disease 2012; 1: 6-11.

  41. Ilyas JA, Vierling JM. An Overview of Emerging Therapies for the Treatment of Chronic Hepatitis C. Clinics in Liver Disease 2011; 15: 515-36.

  42. FDA approves Victrelis for hepatitis C [press release]. US Food and Drug Administration. May 13, 2011.

  43. FDA approves Incivek for hepatitis C [press release]. US Food and Drug Administration. May 23, 2011.

  44. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.

  45. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-76.

  46. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.

  47. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.

  48. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012; 143: 608-18; e601-e605.

  49. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.

  50. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Poordad. 2011. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.

  51. Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, Bengtsson L, et al. Telaprevir substantially improved svrrates across all IL28b genotypes in the ADVANCE trial. J Hepatol 2011; 54: S542-S543.

  52. Kuehn BM. Telaprevir Warning. MSJ. JAMA 2013; 309: 333.

  53. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.

  54. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.

  55. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, et al. IL28b polymorphism predicts virologicresponse in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. J Hepatol 2011; 54: 6.

  56. Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschęnes M, Marotta PJ, Lee SS, et al. Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009; 23: 180-4.

  57. Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14: 6467-72.

  58. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280- 8; e281.

  59. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando- Lemaire V, Beaugrand M, Pol S, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-53.

  60. Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19(Suppl. 2): 1-26.

  61. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl. 1): S88-S100.

  62. Iacobellis A, Siciliano M, Annicchiarico BE, Valvano MR, Niro GA, Accadia L, Caruso N, et al. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009; 30: 146-53.

  63. Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérezdel- Pulgar S, García-Valdecasas JC, Navasa M, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-28.

  64. Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-Lotichius M, et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int 2013; 26: 67-74.

  65. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.

  66. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199: 1-10.

  67. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl 2009; 15: 126-35.

  68. Brown RS. Hepatitis C and liver transplantation. Nature 2005; 436: 973-8.

  69. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.

  70. Everson GT. Should we treat patients with chronic hepatitis C on the waiting list? J Hepatol 2005; 42: 456-62.

  71. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5.

  72. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.

  73. Roche B, Samuel D. Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results. J Hepatol 2009; 50: 652-4.

  74. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-71.

  75. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Kokudo N. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-11.

  76. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-38.

  77. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-56.

  78. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-98.

  79. Berenguer M, Wright TL. Treatment strategies for recurrent hepatitis C after liver transplantation. Clinics in Liver Disease 1999; 3: 883-99.

  80. Berenguer M. Treatment of hepatitis C after liver transplantation. Clinics in Liver Disease 2005; 9: 579- 600, vi.

  81. García-Pajares F, Almohalla C, Lorenzo Pelayo S, Ruiz Zorrilla R, Pinto P, Ramos C, Sanchez Antolin G, et al. Early and extended therapy for recurrent hepatitis C after liver transplantation. Transplant Proc 2012; 44: 1571-3.

  82. Firpi RJ, Dong H, Clark VC, Soldevila-Pico C, Morelli G, Cabrera R, Norkina O, et al. CC genotype donors for the interleukin- 28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int 2013; 33: 72-8.

  83. Saxena V, Terrault N. 2012. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 17: 216-24.

  84. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-7.

  85. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011; 54: 3-5.

  86. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-8.

  87. Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience. J Hepatol 2012; 56: S21-S44.

  88. Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010; 17: 77-90.

  89. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-98.

  90. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009; 16: 377-87.

  91. Thomas HC, Torok ME, Foster GR. Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy. Hepatology 1999; 29: 1333-4.

  92. Pawlotsky JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol 2009; 2: 205-19.

  93. Pawlotsky JM. Treatment failure and resistance with direct- acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-51.

  94. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.

  95. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20: 23-38.

  96. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012; 61(Suppl. 1): i36-i46.

  97. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-77.

  98. Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77: 177-85.

  99. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-7.

  100. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65: 202-12.

  101. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, et al. Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment. J Virol 2013; 87: 1544-53.

  102. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011; 17: 116-21.

  103. Chevaliez S, Pawlotsky JM. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clinics in Liver Disease 2005; 9: 371-382, v.

  104. Hezode C, Dorival C, Zoulim F, Larrey DG, Pol S, Cacoub C. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhoticnon responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology 2012; 56: 191A-1144A.

  105. Poordad FF, Lawitz EJ, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, et al. Randomized trial comparing ribavirin dose reduction versus erythrpoeitin for anemia management in previously untreated patients with chronic hepatitis C receiving Boceprevir plus Peginterferon/ Riba. 47th Annual Meeting of the European Association for the Study of the Liver, April 18-22, 2012, Barcelona, Spain; abstract 1419.

  106. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.

  107. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, Wright TL, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124-9.

  108. Jacobson IM, Kowdley KV, Kwo PY. Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterol Hepatol (NY) 2012; 8: 1-16.

  109. Sulkowski MS, Roberts S, Afdhal N, Andreone P, Diago M, Pol S, Poordad F, et al. 1162 Ribavirin Dose Modification in Treatment-naďve and Previously Treated Patients who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies. J Hepatol 2012; 56: S459-S460.

  110. Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, et al. Hepatitis C virus treatment- related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139: 1602-11; 1611; e1601.

  111. Rosa I. Management of side-effects. Clin Res Hepatol Gastroenterol 2011; 35(Suppl. 2): S69-S74.

  112. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.

  113. Cacoub P, Bourličre M, Lübbe J, Dupin N, Buggisch P, Dusheiko G, Hézode C, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56: 455-63.

  114. Yu D, Feld JJ. HCV protease inhibitors: using the evidence to guide clinical practice. Clinical Investigation 2012; 2: 923-37.

  115. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005; 54: 1-17.

  116. Reitsma AM, Closen ML, Cunningham M, Lombardo PA, Minich HN, Moreno JD, Nichols RL, et al. Infected physicians and invasive procedures: safe practice management. Clin Infect Dis 2005; 40: 1665-72.

  117. Leigh JP, Gillen M, Franks P, Sutherland S, Nguyen HH, Steenland K, Xing G. Costs of needlestick injuries and subsequent hepatitis and HIV infection. Curr Med Res Opin 2007; 23: 2093-105.

  118. Pruss-Ustun A, Rapiti E, Hutin Y. Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med 2005; 48: 482-90.

  119. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31: 756-62.

  120. Zuckerman J, Clewley G, Griffiths P, Cockcroft A. Prevalence of hepatitis C antibodies in clinical health-care workers. Lancet 1994; 343: 1618-20.

  121. Yazdanpanah Y, De Carli G, Migueres B, Lot F, Campins M, Colombo C, Thomas T, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005; 41: 1423-30.

  122. Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997; 315: 333-7.

  123. MacCannell T, Laramie ak, Gomaa A, Perz JF. Occupational exposure of health care personnel to hepatitis B and hepatitis C: prevention and surveillance strategies. Clinics in Liver Disease 2010; 14: 23-36, vii.

  124. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39.

  125. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.

  126. Occupational exposure to bloodborne pathogens; needlestick and other sharps injuries; final rule. Occupational Safety and Health Administration (OSHA), Department of Labor. Final rule; request for comment on the Information Collection (Paperwork) Requirements. Fed Regist 2001; 66: 5318-25.

  127. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-S20.

  128. Le Campion A, Larouche A, Fauteux-Daniel S, Soudeyns H. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses 2012; 4: 3531-50.

  129. Valladares G, Chacaltana A, Sjogren MH. The management of HCV-infected pregnant women. Ann Hepatol 2010; 9(Suppl.): 92-7.

  130. Rostami Z, Nourbala MH, Alavian SM, Bieraghdar F, Jahani Y, Einollahi B. The impact of Hepatitis C virus infection on kidney transplantation outcomes: A systematic review of 18 observational studies: The impact of HCV on renal transplantation. Hepat Mon 2011; 11: 247-54.

  131. Kershenobich D. Treatment of HCV infected patients and renal disease. Ann Hepatol 2010; 9(Suppl.): 103-6.

  132. Ayaz C, Celen MK, Yuce UN, Geyik MF. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008; 14: 255-9.

  133. Liu CH, Liang CC, Liu CJ, Lin JW, Chen SI, Hung PH, Tsai HB, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 2010; 51: 541-9.

  134. Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13.

  135. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-67.

  136. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palů G, Reiss P, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.

  137. Abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases. November 9- 13, 2012. Boston, Massachusetts, USA. Hepatology 2012; 56(Suppl. 1): 191A-1144A.

  138. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert DK. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 279-90.

  139. Cammŕ C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-60.

  140. Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492-9.

  141. Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12: 1791-8.

  142. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, et al. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C. N Engl J Med 2013; 368: 34-44.

  143. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, et al. Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. N Engl J Med 2013; 368: 45-53.

  144. Méndez-Sánchez N, Gadano A, Soza A, Alves de Mattos A, Marroni CA, Galoppo M, Kershenobich D, et al. Latin American Association for the Study of the Liver Practice Guidelines. Diagnosis, management, and treatment of hepatitis C. Ann Hepatol 2010; 9(Suppl.): 8-26.

  145. Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology & Therapeutics 2012; 35: 647-62.




2020     |     www.medigraphic.com